<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007969</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068358</org_study_id>
    <secondary_id>QLT-VFI-PDV-01</secondary_id>
    <secondary_id>QLT-PHO-VFI-PDV-01</secondary_id>
    <nct_id>NCT00007969</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma</brief_title>
  <official_title>A Phase 1/2 Uncontrolled, Open Label Study Of Photodynamic Vaccination In Patients With Stage III/IV Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to&#xD;
      light to kill tumor cells. Photodynamic therapy may be effective in treating melanoma.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of photodynamic therapy in treating&#xD;
      patients who have stage III or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety of photodynamic therapy with verteporfin and Detox-B&#xD;
      adjuvant in patients with stage III or IV melanoma. II. Determine the clinical response in&#xD;
      patients treated with this regimen. III. Determine whether this regimen induces systemic&#xD;
      cellular and humoral immune responses to melanoma antigens in these patients. IV. Determine&#xD;
      the ablation of cutaneous tumors in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients undergo photodynamic therapy with verteporfin&#xD;
      and Detox-B adjuvant. Treatment repeats every 2 weeks for a total of 3 courses, each to a&#xD;
      different melanoma lesion. Both non-treated and treated tumors are measured prior to study&#xD;
      and at months 2, 4, and 6. Immune profile is also assessed prior to study and at months 2, 4,&#xD;
      and 6.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Detox-B adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verteporfin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of stage III or IV melanoma At least 3 cutaneous tumors&#xD;
        for treatment (treatment tumors) AND 1-7 additional cutaneous, visceral, or lymph node&#xD;
        tumors for response assessment (marker tumors) Treatment tumors must be on trunk, arms, or&#xD;
        legs AND be 1.0-3.6 cm in longest dimension Measurable disease by calipers or CT scan No&#xD;
        CNS metastases by CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: WBC at least 2,500/mm3 Neutrophil count at least 1,000/mm3&#xD;
        Platelet count at least 50,000/mm3 Hemoglobin at least 9 g/dL Hematocrit at least 27%&#xD;
        Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST/ALT no greater&#xD;
        than 2 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no&#xD;
        greater than 2 times ULN&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy&#xD;
        or immunotherapy No concurrent biologic therapy Chemotherapy: At least 4 weeks since prior&#xD;
        chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At&#xD;
        least 4 weeks since prior radiotherapy No concurrent radiotherapy Surgery: No concurrent&#xD;
        surgical removal of melanoma lesions designated for treatment or response assessment Other:&#xD;
        No other concurrent therapy for melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graeme R. Boniface, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>QLT Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center at Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>January 6, 2001</study_first_submitted>
  <study_first_submitted_qc>March 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2004</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
    <mesh_term>Detox adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

